Comparison of Outcomes for Patients with Primary Sclerosing Cholangitis Associated with Ulcerative Colitis and Crohn's Disease

Overview

Journal Gastroenterol Rep (Oxf)

Specialty Gastroenterology

Date 2014 Oct 31

PMID 25355801

Citations 14

Authors

Udayakumar Navaneethan

Preethi Gk Venkatesh

Ramprasad Jegadeesan

Vennisvasanth Lourdusamy

Jeffrey P Hammel

Ravi P Kiran

Bo Shen

Affiliations

Soon will be listed here.

Abstract

Background: The comparative outcomes of ulcerative colitis (UC) and Crohn's disease (CD) in patients with primary sclerosing cholangitis (PSC) are unclear; the aim of our study was to make an objective comparison.

Methods: A total of 273 patients with PSC and inflammatory bowel disease (223 with UC and 50 with CD) were included. Clinical and demographic variables were obtained.

Results: The PSC risk score was similar for both groups. The median follow-up period in patients with PSC-UC was 12 years (range 0-38) and that for PSC-CD was 14 years (range 1-36). The median number of disease flares per year was higher in PSC-UC patients than in the PSC-CD group [1vs.0 (ranges 0-20 and 0-9, respectively); P < 0.001]. More patients with UC developed colon neoplasia than CD (35.9% vs.18%; P = 0.009). On proportional hazards analysis for the risk of colectomy, UC patients had a 12% higher risk for colectomy [hazard ratio (HR) = 0.88; 95% confidence interval (CI) 0.51-1.51; P = 0.64]. Liver transplantation for PSC was associated with decreased risk (HR = 0.57; 95% CI 0.37-0.89; P = 0.013), while colon neoplasia increased the risk (HR = 3.83; 95% CI 2.63-5.58; P < 0.001) for colectomy. On proportional hazards analysis for the risk of colon neoplasia, UC patients had 56% higher risk of developing colon neoplasia than CD (HR = 0.44; 95% CI 0.16-1.25; P = 0.12).

Conclusions: PSC patients with CD appear to be associated with a lower risk of colon neoplasia and colectomy than PSC patients with UC.

Citing Articles

Evaluation of Mayo endoscopic subscore in ulcerative colitis with concomitant primary sclerosing cholangitis.

Liu X, Sun X World J Gastrointest Endosc. 2025; 17(2):103448.

PMID: 39989857 PMC: 11843038. DOI: 10.4253/wjge.v17.i2.103448.

Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)-A European Society of Organ Transplantation (ESOT) Consensus Statement.

Carbone M, Della Penna A, Mazzarelli C, De Martin E, Villard C, Bergquist A Transpl Int. 2023; 36:11729.

PMID: 37841645 PMC: 10570452. DOI: 10.3389/ti.2023.11729.

Incidence and adverse clinical events of primary sclerosing cholangitis with ulcerative colitis.

Han I, Baek D, Hong S, Lee B, Lee M, Kim G Int J Colorectal Dis. 2023; 38(1):175.

PMID: 37349585 DOI: 10.1007/s00384-023-04464-z.

Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology.

Eder P, Lodyga M, Gawron-Kiszka M, Dobrowolska A, Gonciarz M, Hartleb M Prz Gastroenterol. 2023; 18(1):1-42.

PMID: 37007752 PMC: 10050986. DOI: 10.5114/pg.2023.125882.

Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India.

Singh A, Midha V, Narang V, Kedia S, Mahajan R, Dhoble P Intest Res. 2022; 21(4):452-459.

PMID: 36453008 PMC: 10626019. DOI: 10.5217/ir.2022.00087.

References

Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M . Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126(2):451-9. DOI: 10.1053/j.gastro.2003.11.010. View

Navaneethan U, Kochhar G, Venkatesh P, Lewis B, Lashner B, Remzi F . Duration and severity of primary sclerosing cholangitis is not associated with risk of neoplastic changes in the colon in patients with ulcerative colitis. Gastrointest Endosc. 2012; 75(5):1045-1054.e1. DOI: 10.1016/j.gie.2012.01.015. View

Broome U, Lofberg R, Veress B, Eriksson L . Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. 1995; 22(5):1404-8. DOI: 10.1002/hep.1840220511. View

Mary J, Modigliani R . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989; 30(7):983-9. PMC: 1434265. DOI: 10.1136/gut.30.7.983. View

Rubin D, Huo D, Kinnucan J, Sedrak M, McCullom N, Bunnag A . Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013; 11(12):1601-8.e1-4. PMC: 3840031. DOI: 10.1016/j.cgh.2013.06.023. View

Satsangi J, Silverberg M, Vermeire S, Colombel J . The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55(6):749-53. PMC: 1856208. DOI: 10.1136/gut.2005.082909. View

Navaneethan U, Shen B . Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010; 16(9):1598-619. DOI: 10.1002/ibd.21219. View

Navaneethan U, Venkatesh P, Mukewar S, Lashner B, Remzi F, McCullough A . Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2012; 10(5):540-6. DOI: 10.1016/j.cgh.2012.01.006. View

Navaneethan U, Venkatesh P, Lashner B, Lopez R, Kiran R, Shen B . Severity of primary sclerosing cholangitis and its impact on the clinical outcome of Crohn's disease. J Crohns Colitis. 2012; 6(6):674-80. DOI: 10.1016/j.crohns.2011.11.020. View

10.

Greenstein A, Sachar D, Smith H, Janowitz H, AUFSES Jr A . A comparison of cancer risk in Crohn's disease and ulcerative colitis. Cancer. 1981; 48(12):2742-5. DOI: 10.1002/1097-0142(19811215)48:12<2742::aid-cncr2820481231>3.0.co;2-p. View

11.

Munkholm P, Langholz E, Davidsen M, Binder V . Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology. 1993; 105(6):1716-23. DOI: 10.1016/0016-5085(93)91068-s. View

12.

Halliday J, Djordjevic J, Lust M, Culver E, Braden B, Travis S . A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease. J Crohns Colitis. 2012; 6(2):174-81. DOI: 10.1016/j.crohns.2011.07.015. View

13.

Shetty K, Rybicki L, Brzezinski A, Carey W, Lashner B . The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. 1999; 94(6):1643-9. DOI: 10.1111/j.1572-0241.1999.01156.x. View

14.

Schroeder K, Tremaine W, Ilstrup D . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317(26):1625-9. DOI: 10.1056/NEJM198712243172603. View

15.

Broome U, Bergquist A . Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis. 2006; 26(1):31-41. DOI: 10.1055/s-2006-933561. View

16.

Persson P, Karlen P, Bernell O, Leijonmarck C, Brostrom O, Ahlbom A . Crohn's disease and cancer: a population-based cohort study. Gastroenterology. 1994; 107(6):1675-9. DOI: 10.1016/0016-5085(94)90807-9. View

17.

Gillen C, Walmsley R, Prior P, Andrews H, Allan R . Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut. 1994; 35(11):1590-2. PMC: 1375617. DOI: 10.1136/gut.35.11.1590. View

18.

Lindstrom L, Lapidus A, Ost A, Bergquist A . Increased risk of colorectal cancer and dysplasia in patients with Crohn's colitis and primary sclerosing cholangitis. Dis Colon Rectum. 2011; 54(11):1392-7. DOI: 10.1097/DCR.0b013e31822bbcc1. View

19.

Loftus Jr E, Harewood G, Loftus C, Tremaine W, Harmsen W, Zinsmeister A . PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2004; 54(1):91-6. PMC: 1774346. DOI: 10.1136/gut.2004.046615. View

20.

Gyde S, Prior P, Macartney J, Thompson H, Waterhouse J, Allan R . Malignancy in Crohn's disease. Gut. 1980; 21(12):1024-9. PMC: 1419401. DOI: 10.1136/gut.21.12.1024. View